Install Free Gold Price Widget!
Install Free Gold Price Widget!
Install Free Gold Price Widget!
|
- $450 Error Nukes Novo Nordisk’s Ozempic Patent, Opening . . .
Novo Nordisk (NYSE: NVO) has permanently forfeited Canadian patent protection for semaglutide—the blockbuster active ingredient in Ozempic and Wegovy—after failing to pay a routine $450 maintenance invoice in 2019 Under Canada’s Patent Act, once a missed-fee grace period lapses, rights “cannot be revived,” formally clearing the way for rival filings Canadian maintenance charges
- Ozempic Patent Expires In Canada After Novo Nordisk Fails To . . .
According to the Canadian Patent Database, patent number CA-2601784 concerning Novo Nordisk’s GLP-1 compounds is currently “expired and beyond the Period of Reversal,” following multiple
- Novo Nordisks Canadian Mistake - Science | AAAS
I posted this on my BlueSky account and a follower there (Prof Michael Hoffman from Toronto) put me on to the Canadian Patent Database, where you can find that Novo did file a patent there for semaglutide but the last time they paid the annual maintenance fee on it was 2018! You can even find a letter where their lawyers send a refund
- Did Novo open the Canadian market to GLP-1 generics?
What Novo Nordisk stands to lose in Canada and beyond The expiry of Novo Nordisk’s semaglutide patent in Canada might look small on paper, but the consequences could be substantial “There is no question that generic manufacturers are preparing for launch as soon as the Novo data exclusivity expires in January 2026
- Novo Nordisk lets key Ozempic patent lapse in Canada, despite . . .
A letter from 2017 shows counsel requested that the maintenance fee paid that year (US$250) be refunded (March 20, 2017 Government of Canada letter) “preferring instead to wait until the period of grace” Two years later, the Canadian patent office stated that Novo Nordisk had yet to pay its fees and owed it over US$450 Why Canada?
- A $250 mistake will cost Ozempic maker Novo Nordisk billions
In 2019, the Canadian patent office sent Novo Nordisk a letter saying it hadn’t received their fee, and that it was now $450 Lowe discovered that ultimately the company never paid the
- The story of how Novo Nordisk will lose billions because it . . .
In 2019, the Canadian patent office sent a letter saying it hadn’t received Novo Nordisk’s annual $250 maintenance fee on time, but the company could maintain the patent by paying a total of $450
|
|
|